Literature DB >> 8266386

Lipoprotein(a) and ischemic cerebrovascular disease in young adults.

M Nagayama1, Y Shinohara, T Nagayama.   

Abstract

BACKGROUND AND
PURPOSE: Serum lipoprotein(a) level is genetically determined and remains almost constant throughout life. Based on this property, we investigated the serum lipoprotein(a) levels of ischemic stroke patients in the chronic stage (mean period after stroke, 27 months) and its relation to the types of ischemic stroke.
METHODS: We measured serum lipoprotein(a) levels in 101 patients with chronic ischemic stroke and 37 normal control subjects, taking the clinical profiles into consideration.
RESULTS: Lipoprotein(a) levels in patients with atherothrombotic stroke were 28.0 +/- 19.6 mg/dL (mean +/- SD), which were significantly (P < .01) higher than those in patients with lacunar stroke and in normal control subjects (16.4 +/- 13.5 and 11.7 +/- 10.5 mg/dL, respectively). The lipoprotein(a) levels in patients with atherothrombotic stroke were significantly higher in the subgroup who were a younger age at onset: onset before age 50 years, 35.3 +/- 20.5; onset at age 50 to 59, 35.4 +/- 21.7; onset at age 60 to 69, 17.0 +/- 12.8; and onset at age 70 or older, 16.3 +/- 6.8 mg/dL (P < .01 for onset before age 50 versus 60 to 69 years or 70 years or older; P < .01 for onset at 50 to 59 years versus 60 to 69 years or 70 years or older). Serum lipoprotein(a) was significantly increased (40.2 +/- 20.1 mg/dL) in young adults with atherothrombotic stroke (onset at younger than age 45 years) compared with that in patients older than 45 years (P < .01).
CONCLUSIONS: We conclude that lipoprotein(a) is a genetic, independent, and critical risk factor for ischemic stroke, especially in young adults.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8266386     DOI: 10.1161/01.str.25.1.74

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  8 in total

Review 1.  The relationship between cholesterol and stroke: implications for antihyperlipidaemic therapy in older patients.

Authors:  C Sarti; M Kaarisalo; J Tuomilehto
Journal:  Drugs Aging       Date:  2000-07       Impact factor: 3.923

Review 2.  Association of physical activity level and stroke outcomes in men and women: a meta-analysis.

Authors:  Lien Diep; John Kwagyan; Joseph Kurantsin-Mills; Roger Weir; Annapurni Jayam-Trouth
Journal:  J Womens Health (Larchmt)       Date:  2010-10       Impact factor: 2.681

Review 3.  Lipoprotein (a) and stroke.

Authors:  H J Milionis; A F Winder; D P Mikhailidis
Journal:  J Clin Pathol       Date:  2000-07       Impact factor: 3.411

4.  Serum lipids in young patients with ischaemic stroke: a case-control study.

Authors:  J F Albucher; J Ferrieres; J B Ruidavets; B Guiraud-Chaumeil; B P Perret; F Chollet
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-07       Impact factor: 10.154

5.  Increased stroke risk and lipoprotein(a) in a multiethnic community: the Northern Manhattan Stroke Study.

Authors:  Bernadette Boden-Albala; Douglas E Kargman; I-Feng Lin; Myunghee C Paik; Ralph L Sacco; Lars Berglund
Journal:  Cerebrovasc Dis       Date:  2010-07-23       Impact factor: 2.762

6.  Lipoprotein (a) level, apolipoprotein (a) size, and risk of unexplained ischemic stroke in young and middle-aged adults.

Authors:  Azadeh Beheshtian; Sanyog G Shitole; Alan Z Segal; Dana Leifer; Russell P Tracy; Daniel J Rader; Richard B Devereux; Jorge R Kizer
Journal:  Atherosclerosis       Date:  2016-08-20       Impact factor: 5.162

7.  Risk index for predicting perioperative stroke, myocardial infarction, or death risk in asymptomatic patients undergoing carotid endarterectomy.

Authors:  Prateek K Gupta; Bala Ramanan; Jason N Mactaggart; Abhishek Sundaram; Xiang Fang; Himani Gupta; Jason M Johanning; Iraklis I Pipinos
Journal:  J Vasc Surg       Date:  2012-11-15       Impact factor: 4.268

Review 8.  Screening for hypercoagulable syndromes following stroke.

Authors:  Cheryl Bushnell; Larry B Goldstein
Journal:  Curr Atheroscler Rep       Date:  2003-07       Impact factor: 5.113

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.